RETRACTED: Screening of Clinical Factors Related to Prognosis of Breast Cancer Based on the Cox Proportional Risk Model (Retracted article. See vol. 29, pg. 597, 2022)

被引:2
作者
Tang, Wan [1 ]
Mu, Degong [1 ]
Han, Ling [2 ]
Guo, Xianmin [1 ]
Han, Bing [3 ]
Song, Dong [3 ]
机构
[1] First Hosp Jilin Univ, Third Operating Room, Changchun 130021, Jilin, Peoples R China
[2] First Hosp Jilin Univ, Joint Surg Dept, Changchun, Jilin, Peoples R China
[3] First Hosp Jilin Univ, Dept Breast Surg, Changchun 130021, Jilin, Peoples R China
关键词
breast cancer; clinical prognostic factors; Cox risk regression model analysis; ADJUVANT CHEMOTHERAPY; FOLLOW-UP; TRASTUZUMAB; RADIOTHERAPY; METASTASES; PHYSIOLOGY;
D O I
10.1089/cmb.2019.0110
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Proper evaluation of the relevant clinical factors for the prognosis of breast cancer is particularly important in the selection of appropriate therapeutic strategies. To further screen and identify the clinically significant factors associated with breast cancer, the Cox risk regression model analysis was performed in this study. The follow-up data of intact breast cancer patients were downloaded from METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) database, and the prognostic factors correlated with radiotherapy factors were screened using the Cox risk regression model analysis of prognostic factors. The response of different clinical features to radiotherapy was also evaluated by survival prognosis analysis and prediction. A total of 1980 breast cancer patients were enrolled in this study, including 1173 patients who received the radiotherapy treatment and 807 patients without radiotherapy treatment. To further study the correlation between the clinical prognostic factors and the overall survival, the single factor and multivariate Cox regression analysis were performed, and the clinical prognostic factors implied that the patients with age <60 years, receiving radiotherapy, grade 1, stage 0-1, or human epidermal growth factor receptor 2 (HER2) negative had a better overall clinical survival. The association analysis of the radiotherapy treatment and the clinical prognostic factors implied that the patients with younger age, stage lower, or HER2 negative showed a better overall clinical survival, and the patients who received radiotherapy had a better 3-year survival probability and 5-year survival probability. Screening and identifying the clinically significant factors associated with breast cancer can help predict the risk of disease. Age, stage, or HER2 status was the prognostic factors correlated with radiotherapy treatment.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 31 条
[1]   THYROID FOLLICULAR CARCINOMA WITH PULMONARY METASTASES IN A BEAVER (CASTOR-CANADENSIS) [J].
ANDERSON, WI ;
SCHLAFER, DH ;
VESELY, KR .
JOURNAL OF WILDLIFE DISEASES, 1989, 25 (04) :599-600
[2]   Treatment of HER2-positive breast cancer: current status and future perspectives [J].
Arteaga, Carlos L. ;
Sliwkowski, Mark X. ;
Osborne, C. Kent ;
Perez, Edith A. ;
Puglisi, Fabio ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (01) :16-32
[3]   Radiotherapy for breast cancer in countries with limited resources: Program implementation and evidence-based recommendations [J].
Bese, NS ;
Kiel, K ;
El-Gueddari, BEK ;
Campbell, OB ;
Awuah, B ;
Vikram, B .
BREAST JOURNAL, 2006, 12 (01) :S96-S102
[4]   Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI [J].
Budde, Matthew D. ;
Gold, Eric ;
Jordan, E. Kay ;
Frank, Joseph A. .
CLINICAL & EXPERIMENTAL METASTASIS, 2012, 29 (01) :51-62
[5]   11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].
Cameron, David ;
Piccart-Gebhart, Martine J. ;
Gelber, Richard D. ;
Procter, Marion ;
Goldhirsch, Aron ;
de Azambuja, Evandro ;
Castro, Gilberto, Jr. ;
Untch, Michael ;
Smith, Ian ;
Gianni, Luca ;
Baselga, Jose ;
Al-Sakaff, Nedal ;
Lauer, Sabine ;
McFadden, Eleanor ;
Leyland-Jones, Brian ;
Bell, Richard ;
Dowsett, Mitch ;
Jackisch, Christian .
LANCET, 2017, 389 (10075) :1195-1205
[6]   Second solid cancers after radiotherapy for breast cancer in SEER cancer registries [J].
de Gonzalez, A. Berrington ;
Curtis, R. E. ;
Gilbert, E. ;
Berg, C. D. ;
Smith, S. A. ;
Stovall, M. ;
Ron, E. .
BRITISH JOURNAL OF CANCER, 2010, 102 (01) :220-226
[7]  
Efird Jimmy T, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030062
[8]   PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].
ELSTON, CW ;
ELLIS, IO .
HISTOPATHOLOGY, 1991, 19 (05) :403-410
[9]   On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve [J].
Eng, Kevin H. ;
Schiller, Emily ;
Morrell, Kayla .
ONCOTARGET, 2015, 6 (34) :36308-36318
[10]   Immunization of metastatic breast cancer patients with a fully synthetic globe H conjugate: A phase I trial [J].
Gilewski, T ;
Ragupathi, G ;
Bhuta, S ;
Williams, LJ ;
Musselli, C ;
Zhang, XF ;
Bencsath, KP ;
Panageas, KS ;
Chin, J ;
Hudis, CA ;
Norton, L ;
Houghton, AN ;
Livingston, PO ;
Danishefsky, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3270-3275